Please login to the form below

Not currently logged in

NICE denies pharma influence on statin guidance

Responds to accusations committee members were ‘in the pay’ of drug firms
National Institute for Health and Care Excellence NICE logo

UK health watchdog the National Institute for Heath and Care Excellence (NICE) has shot down claims that the pharma industry influenced new guidance to increase the use of drugs to lower cholesterol.

Last month NICE published new draft guidelines to lower the threshold for NHS patients in England and Wales to take statins from those with a 20 per cent risk of developing cardiovascular disease (CVD) to those with a 10 per cent risk.

This decision was due to several factors, including new evidence on the effectiveness of risk assessment tools for CVD, as well as the entry onto the market of generic versions of Pfizer's Lipitor (atorvastatin), making statin treatment vastly cheaper.

However, the Sunday Express newspaper published a story at the weekend which claimed the experts behind the guidance were 'in the pay' of the pharma companies who manufacture the drugs, influencing the decision to increase prescribing despite potential side effects.

According to the article, an investigation by the paper discovered eight out of 12 members of the NICE panel have financial ties to the drug firms, including payments for speeches, lectures and conference attendance, as well as salaries to conduct clinical trials.

NICE has rebutted the Sunday Express story, which failed to mention the launch of cheaper generic statins and their potential to save the NHS £350m a year, according to estimates from the Generic Manufacturers' Association.

'The draft recommendations are centred on the prescribing of generic statins rather than branded versions,' said NICE. 'Since the 2008 guideline was published, atorvastatin has come off patent which means it is now available to the NHS at a much cheaper cost.'

This guidance is in line with other national recommendations, including the American College of Cardiology and the American Heart Association's to update their guidelines at the end of 2013 to cover twice as many people in the US.

NICE also commented on pharma company influence, claiming every member of the expert panel declared their interests to NICE and that these were publically available and deemed not to be specific enough to warrant withdrawal.

One member of the group did withdraw altogether, although only after declaring involvement in a company that sells health checks, not a pharma company.

NICE also responded to a specific accusation from the Express about a member of the panel being paid for their involvement in clinical trials involving cholesterol-lowering drugs.

NICE refuted this, declaring that the group chair Dr Anthony Wierzbicki was involved in a number of such trials but these involved investigational medicines targeted at familial hypercholestrolaemia (FH) – a condition that is the subject of a different guideline.

Article by
Thomas Meek

13th March 2014

From: Sales, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...